Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Michael Trimba

Interventional Pain Medicine Brooklyn, NY Medical Doctor

NPI 1396725081 CMS profile 154289

2417 Ocean Ave, Brooklyn, NY 11229

Open in the dashboard

General payments

$3,203

162 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Michael Trimba of Brooklyn, NY is reported in the CMS Open Payments database as having received $3,203 across 162 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 44th percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $158 8
2024 General $154 6
2023 General $711 31
2022 General $300 15
2021 General $615 32
2020 General $421 25
2019 General $844 45

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michael Trimba
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Michael Trimba were reported at $158. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Michael Trimba Interventional Pain Medicine median Middle half National median
2019 $844 $684 $216–$2,079 $163
2020 $421 $382 $122–$1,109 $114
2021 $615 $552 $167–$1,554 $132
2022 $300 $605 $187–$1,924 $149
2023 $711 $671 $195–$1,915 $160
2024 $154 $684 $206–$1,837 $164
2025 $158 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Sanofi-Aventis U.S. LLC $390 15 payments
  2. Fidia Pharma USA Inc. $337 17 payments
  3. Flexion Therapeutics, Inc. $328 16 payments
  4. Arbor Pharmaceuticals, Inc. $316 18 payments
  5. Scilex Pharmaceuticals Inc. $301 13 payments
  6. Horizon Therapeutics plc $272 17 payments
  7. Salix Pharmaceuticals, a division of Bausch Health US, LLC $245 14 payments
  8. Kowa Pharmaceuticals America, Inc. $199 12 payments
  9. Zimmer Biomet Holdings, Inc. $99 3 payments
  10. Sentynl Therapeutics, Inc. $93 7 payments
  11. Other $622 30 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,182 161 payments
  2. Education $21 1 payment
Products named General payments · program years 2019–2025
  1. SYNVISC-ONE $388 14 payments
  2. Zilretta $328 16 payments
  3. ZTLido $252 11 payments
  4. TRILURON $242 12 payments
  5. HYMOVIS $229 12 payments
  6. PENNSAID $145 9 payments
  7. HYALGAN $136 7 payments
  8. SEGLENTIS $133 8 payments
  9. Horizant $131 7 payments
  10. RELISTOR $128 7 payments
  11. Other $1,864 94 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 22 drugs

Part D claims

993

Median for Interventional Pain Management: 1,220

Drug cost

$92,388

Median for Interventional Pain Management: $39,344

Branded share of claims

45.4%

Median for Interventional Pain Management: 34.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Diclofenac Sodium Generic 88 $30,898
Ztlido Lidocaine Brand 63 $21,418
Lyrica Pregabalin Brand 11 $9,657
Horizant Gabapentin Enacarbil Brand 20 $9,391
Doxepin Hcl Generic 20 $4,014
Diclofenac Sodium Er Diclofenac Sodium Brand 35 $3,102
Oxycodone Hcl Generic 131 $2,633
Naproxen Sodium Generic 21 $2,171
Acetaminophen-Codeine Acetaminophen With Codeine Brand 117 $1,762
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 106 $1,646

The 10 drugs with the highest cost, of 22 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,476 Part D prescribers listed as Interventional Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 58 billing codes

Paid by Medicare

$354,942

Of which drugs: $67,523

Medicare patients

480

Average age 79

Services billed

7,182

310 women, 170 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 71%
Ischemic heart disease 60%
Depression 43%
Heart failure 34%
Chronic kidney disease 28%
COPD 26%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg J3304 Office 54 2,017 $27,796
Hyaluronan or derivative, hyalgan, supartz or visco-3, for intra-articular injection, per dose J7321 Office 76 349 $20,028
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 Office 265 1,403 $7,775
Hyaluronan or derivative, gel-one, for intra-articular injection, per dose J7326 Office 11 14 $5,634
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 20 234 $21

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RELISTOR
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $25
$25 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

162 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record